Beth Schurman, Vice President

Beth Schurman is Vice President of Herspiegel Consulting, a leading boutique consulting firm serving the Pharmaceutical and Biotechnology industries. Her strong leadership, attention to detail and client engagement skills have earned her the trust and respect of her clients. Beth leads teams of consultants and clients to expand their current thinking, structure and analyze business problems, and develop strategic and tactical solutions.

Beth successfully manages client project outcomes by expertly blending marketing strategy, innovative thinking, and rigorous structure to establish market changing strategies and impactful execution. Clients value her team’s ability to smoothly transition from strategy development & innovation to project management and analytics. Beth has led projects across our range of 5 core service areas and spanning therapeutic areas including diabetes, obesity, infectious disease, CNS and oncology.

Prior to her tenure with Herspiegel Consulting, Beth gained extensive marketing experience at both Novo Nordisk and BMS. She was highly involved in product launch, co-promotions and in-line brand management in retail and hospital markets.

Beth has a Bachelor of Arts in Biochemistry and Molecular Biology from Rutgers University. Beth then earned her MBA with specialization in Marketing and Management from the Stern School of Business at NYU.

Latest Blogs

The FDA approved Dupixent for moderate-to-severe atopic dermatitis

April 14, 2017
  The FDA approved Dupixent On March 28th, the FDA approved Dupixent for moderate-to-severe atopic ...
Read more

Why Drug Pricing is in the News Now and What Can Be Done About It?

March 3, 2017
Why drug pricing is in the news now and what can be done about it? From Turing Pharmaceuticals to Mylan,...
Read more

Key Challenges Facing Obamacare Repeal and Replace Plan

February 3, 2017
ACA repeal and replacement complicated by two key challenges...
Read more

How Pharma Can Prepare for the Patent Cliff

February 2, 2017
Extending market exclusivity and responding properly to the volume of recent patent expiries are critica...
Read more